<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01679249</url>
  </required_header>
  <id_info>
    <org_study_id>01249</org_study_id>
    <nct_id>NCT01679249</nct_id>
  </id_info>
  <brief_title>Blood Volume Analysis and Related Outcomes in Hemodialysis</brief_title>
  <official_title>Blood Volume Analysis and Related Outcomes in Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA New York Harbor Healthcare System</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Daxor Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>VA New York Harbor Healthcare System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An understanding of fluid changes that occur during hemodialysis (HD) with ultrafiltration&#xD;
      (UF) is essential for determining the efficacy of HD, as well as for reducing complications&#xD;
      related to hypovolemia or, conversely, chronic volume overload.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Accurate assessment of the BV and distribution of body fluids is essential for&#xD;
      prescribing HD and for reducing complications related to hypovolemia and volume overload.&#xD;
      Monitoring relative changes in BV using hematocrit (Hct), e.g. CLM-III, an indirect method,&#xD;
      cannot be used to determine the absolute levels of BV. Here we report the first study of&#xD;
      isotope BV measurement (IBVM) for assessing volume status in HD patients using indicator&#xD;
      dilutional method.&#xD;
&#xD;
      10 adult HD patients were enrolled in this prospective observational study. Multi-point IBVM&#xD;
      before and after HD was performed using BVA-100 (Daxor, New York, NY). BVA-100 calculates BV&#xD;
      with an accuracy of ±2.5%, by using &lt;25μCi of iodinated I-131 albumin. It assumes normal BV&#xD;
      for a given individual on the basis of patients' deviation from ideal body weight. Fluid loss&#xD;
      from the extravascular component of the extracellular space (EV) was calculated by&#xD;
      subtracting absolute BV change from total weight loss. Intradialytic relative BV changes were&#xD;
      measured by CLM-III during the same HD session. Bland-Altman plot was used to compare&#xD;
      relative BV change pre- and post-HD by IBVM and CLM-III.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Blood volume measurement and comparison to Crit-Line reading</measure>
    <time_frame>Six months</time_frame>
    <description>To compare the results obtained by two different methods of assessing BV: direct measurement of BV using the Blood Volume Analyzer (BVA-100) vs. indirect measurement of relative changes in BV using the Crit-Line Monitor (CLM III). Blood volume is measured in liters and compared with &quot;ideal blood volume&quot; nomograms. Crit-Line Monitor measures relative change in blood volume as a percentage change and does not have absolute values.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">10</enrollment>
  <condition>End Stage Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Hemodialysis patients</arm_group_label>
    <description>Stable prevalent patients on 3-times-per-week hemodialysis</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects will be recruited from the pool of patients at the Dialysis Center at the&#xD;
        Department of Veteran Affairs New York Harbor Healthcare System who are currently&#xD;
        undergoing dialysis for treatment of chronic kidney disease.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;21 years&#xD;
&#xD;
          -  Primary diagnosis of either chronic or acute kidney disease&#xD;
&#xD;
          -  Currently receiving HD treatment&#xD;
&#xD;
          -  Thrice-weekly or twice-weekly HD schedule&#xD;
&#xD;
          -  Treated with standard bicarbonate HD for at least the preceding 6 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant women or nursing mothers&#xD;
&#xD;
          -  Known hypersensitivity to iodine, eggs, albumin or any other component of the Volumex&#xD;
             injection kit&#xD;
&#xD;
          -  Current enrollment in another investigational treatment protocol for dialysis&#xD;
&#xD;
          -  The need to perform hemodialysis with predilution because this will interfere with&#xD;
             measurements of relative blood volume changes (ΔRBV)&#xD;
&#xD;
          -  Kidney transplantation&#xD;
&#xD;
          -  Malignancy requiring chemotherapy&#xD;
&#xD;
          -  Unmeasurable blood pressure with a sphygmomanometer&#xD;
&#xD;
          -  Active hematological disease&#xD;
&#xD;
          -  Active gastrointestinal bleeding&#xD;
&#xD;
          -  Severe malnutrition (predialysis serum albumin &lt;2.6 g/dL)&#xD;
&#xD;
          -  Persistent condition of intradialytic blood pressure instability (hypotensive episodes&#xD;
             in &gt;80% of regular dialysis sessions) within the previous one month period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David S Goldfarb, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA New York Harbor Healthcare System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York Harbor VA Healthcare System Hemodialysis Unit</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>August 31, 2012</study_first_submitted>
  <study_first_submitted_qc>August 31, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2012</study_first_posted>
  <last_update_submitted>September 6, 2012</last_update_submitted>
  <last_update_submitted_qc>September 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>VA New York Harbor Healthcare System</investigator_affiliation>
    <investigator_full_name>David S. Goldfarb, M.D.</investigator_full_name>
    <investigator_title>Chief, Nephrology</investigator_title>
  </responsible_party>
  <keyword>extracellular fluid volume</keyword>
  <keyword>hypotension</keyword>
  <keyword>hemodialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

